Can you predict a man’s risk of prostate cancer 25 years in the future? The data from this study indicates that PSA levels before age 50 is an indicator of future prostate cancer. Find out more about the prospective study conducted by a team of researchers from Memorial Sloane Kettering. Epidemiologist Andrew Vickers talks with host Dr. Bill Rutenberg about what the GP can take from this study What does a slightly elevated, but not high PSA indicate about the chance of prostate cancer in the future?
Prostate Cancer Predictability: Can We Anticipate a Patient's Risk in 25 Years?
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Can you predict a man’s risk of prostate cancer 25 years in the future? The data from this study indicates that PSA levels before age 50 is an indicator of future prostate cancer. Find out more about the prospective study conducted by a team of researchers from Memorial Sloane Kettering. Epidemiologist Andrew Vickers talks with host Dr. Bill Rutenberg about what the GP can take from this study What does a slightly elevated, but not high PSA indicate about the chance of prostate cancer in the future?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
0.50 credits
<p>IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE Broadcast Replay
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
1.00 credits
<p>Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
CME/CE
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
1.00 credits
<p>Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers</p>
CME/CE
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
<p>FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure</p>
MinuteCE®
First-line Chemotherapy Options in Metastatic PDAC
0.25 credits
<p>First-line Chemotherapy Options in Metastatic PDAC</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?